Guideline on follicular lymphoma published in Germany

23

Jul 2020

A new guideline on follicular lymphoma (FL) has been published as part of the oncology guideline program. The guideline was developed by 64 experts from 21 specialist societies and organizations under the supervision of the German Society for Hematology and Medical Oncology (DGHO).

The FL is clinically very heterogeneous. According to the Robert Koch Institute, 3,100 patients develop follicular lymphoma in Germany every year. Women are affected more often than men; the average age of disease debut is 66 years.

The new guideline is intended to optimize care and ensure a quality-assured therapy concept in the case of initial illness and relapse. The new guideline provides recommendations for radiation therapy in combination with system therapy for the early stage of the disease. With limited radiation therapy, relapses can occur outside of the radiation area. For this reason, additional treatment with immunotherapy in the form of accompanying antibody treatment may be appropriate.

In an advanced stage of the disease, treatment aims to alleviate disease-related symptoms and to prolong progression-free survival and overall survival. The choice of therapy strongly depends on the symptoms, the clinical course, and the tumor burden. In symptom-free patients in advanced stages, a watch-and-wait approach should be followed, that is, wait-and-see observation.

However, according to the guideline, patients with high tumor burden who suffer from symptoms should be treated with a combination of chemotherapy and antibody therapy, provided that they have no treatment restrictions.

The guideline in German can be found here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

29

Jul 2021

In early July 2021, two more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, nineteen health apps are now available at the DiGA Directory.

Read more

26

Jul 2021

The revised EBM (German Uniform Evaluation Standard) catalog came into force on July 1, 2021. Three biomarker tests in breast cancer, a number of services related to cryopreservation of egg and sperm cells in young cancer patients, new services dedicated to prenatal testing of the fetal rhesus factor, services concerning the delivery of brachytherapy in prostate cancer were introduced.

Read more

21

Jul 2021

On July 7, 2021, the Federal Joint Committee (G-BA) has launched an online database of method evaluations for conceptually new diagnostic and treatment methods (§135 SGB V), diagnostic and treatment methods in hospital settings (§137c SGB V) and within the framework of co-funded studies (§137e SGB V).

Read more

09

Jul 2021

In June 2021, twelve clinical guidelines were released in Russia: perforated ulcer, bronchial asthma, multiple pregnancy, and others. Furthermore, the orders on the approval of the several standards of medical care entered into force, including standards for the provision of medical care for adults with ischemic heart disease, atrial fibrillation and flutter, and pulmonary hypertension, including chronic thromboembolic pulmonary hypertension.

Read more

08

Jul 2021

On June 19, 2021, two more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, seventeen health apps are now available at the DiGA Directory.

Read more